Posted by Michael Wonder on 25 Sep 2018
Companies stepping up efforts to ensure medicine supply post Brexit
24 September 2018 - Focus is now on 39 centrally authorised medicines, down from 108.
The EMA has revised the number of centrally authorised medicines for which, based on current knowledge, there are concerns of Brexit-related supply disruptions from 108 to 39.
This revision results from EMA’s follow-up activities with the marketing authorisation holders of the 108 medicines that were identified as deemed to be at risk of supply shortages once the United Kingdom leaves the European Union on 29 March 2019 in EMA’s survey on industry preparedness earlier this year.
